Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamizi, Salima, Freyer, Gilles, Bakrin, Naoual, Henin, Emilie, Mohtaram, Amina, Le Saux, Olivia, Falandry, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575209/
https://www.ncbi.nlm.nih.gov/pubmed/23430730
http://dx.doi.org/10.2147/OTT.S27733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575209/
https://www.ncbi.nlm.nih.gov/pubmed/23430730
http://dx.doi.org/10.2147/OTT.S27733

Ejemplares similares